

## 2020 Merit-based Incentive Payment System (MIPS) Measure Changes

Deleted/Modified/Added Measures and Activities			
Performance Category	Deleted – no longer available for 2020 reporting	Modified – make changes for 2020 reporting	Added – newly available for 2020 reporting
<b>Quality</b>	<ul style="list-style-type: none"> <li>• <b>Quality ID 046:</b> Medication Reconciliation Post-Discharge</li> <li>• <b>Quality ID 051:</b> Chronic Obstructive Pulmonary Disease (COPD): Spirometry Evaluation</li> <li>• <b>Quality ID 068:</b> Hematology: Myelodysplastic Syndrome (MDS): Documentation of Iron Stores in Patients Receiving Erythropoietin Therapy</li> <li>• <b>Quality ID 091:</b> Acute Otitis Externa (AOE): Topical Therapy</li> <li>• <b>Quality ID 109:</b> Osteoarthritis (OA): Function and Pain Assessment</li> <li>• <b>Quality ID 131:</b> Pain Assessment and Follow-Up</li> <li>• <b>Quality ID 160:</b> HIV/AIDS: Pneumocystis Jiroveci Pneumonia (PCP) Prophylaxis</li> <li>• <b>Quality ID 165:</b> Coronary Artery Bypass Graft (CABG): Deep Sternal Wound Infection Rate</li> <li>• <b>Quality ID 166:</b> Coronary Artery Bypass Graft (CABG): Stroke</li> <li>• <b>Quality ID 179:</b> Rheumatoid Arthritis (RA): Assessment and Classification of Disease Prognosis</li> <li>• <b>Quality ID 192:</b> Cataracts: Complications within 30 Days Following Cataract Surgery Requiring Additional Surgical Procedures</li> <li>• <b>Quality ID 223:</b> Functional Status Change for Patients</li> </ul>	<p><i>Changes made to the below measures vary and may include revisions to the description, added exclusions, numerator criteria, and/or denominator criteria.</i></p> <ul style="list-style-type: none"> <li>• <b>Quality ID 001:</b> Diabetes: Hemoglobin A1c (HbA1c) Poor Control (&gt;9%)</li> <li>• <b>005:</b> Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) or Angiotensin Receptor-Nepriylsin Inhibitor (ARNI) Therapy for Left Ventricular Systolic Dysfunction (LVSD)</li> <li>• <b>007:</b> Coronary Artery Disease (CAD): Beta-Blocker Therapy – Prior Myocardial Infarction (MI) or Left Ventricular Systolic Dysfunction (LVEF &lt; 40%)</li> <li>• <b>008:</b> Heart Failure (HF): Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD)</li> <li>• <b>009:</b> Anti-Depressant Medication Management</li> <li>• <b>019:</b> Diabetic Retinopathy: Communication with the Physician Managing Ongoing Diabetes Care</li> <li>• <b>066:</b> Appropriate Testing for Children with Pharyngitis</li> <li>• <b>076:</b> Prevention of Central Venous Catheter (CVC) - Related Bloodstream Infection</li> <li>• <b>102:</b> Prostate Cancer: Avoidance of Overuse of Bone Scan for staging Low Risk Prostate Cancer Patients</li> <li>• <b>107:</b> Adult Major Depressive Disorder (MDD): Suicide Risk Assessment</li> <li>• <b>110:</b> Preventive Care and Screening: Influenza Immunization</li> <li>• <b>111:</b> Pneumococcal Vaccination Status for Older Adults</li> <li>• <b>112:</b> Breast Cancer Screening</li> </ul>	<ul style="list-style-type: none"> <li>• <b>Quality ID 476:</b> International Prostate Symptom Score (IPSS) or American Urological Association-Symptom Index (AUA-SI) Change 6-12 Months After Diagnosis of Benign Prostatic Hyperplasia</li> <li>• <b>Quality ID 477:</b> Multimodal Pain Management</li> <li>• <b>Quality ID 478:</b> Functional Status Change for Patients with Neck Impairments</li> </ul>

<p><b>Quality</b></p>	<p>with General Orthopedic Impairments</p> <ul style="list-style-type: none"> <li>• <b>Quality ID 255:</b> Rh Immunoglobulin (Rhogam) for Rh-Negative Pregnant Women at Risk of Fetal Blood Exposure</li> <li>• <b>Quality ID 262:</b> Image Confirmation of Successful Excision of Image-Localized Breast Lesion</li> <li>• <b>Quality ID 271:</b> Inflammatory Bowel Disease (IBD): Preventive Care: Corticosteroid Related Iatrogenic Injury – Bone Loss Assessment</li> <li>• <b>Quality ID 325:</b> Adult Major Depressive Disorder (MDD): Coordination of Care of Patients with Specific Comorbid Conditions</li> <li>• <b>Quality ID 328:</b> Pediatric Kidney Disease: ESRD Patients Receiving Dialysis: Hemoglobin Level &lt; 10 g/dL</li> <li>• <b>Quality ID 329:</b> Adult Kidney Disease: Catheter Use at Initiation of Hemodialysis</li> <li>• <b>Quality ID 330:</b> Adult Kidney Disease: Catheter Use for Greater Than or Equal to 90 Days</li> <li>• <b>Quality ID 343:</b> Screening Colonoscopy Adenoma Detection Rate</li> <li>• <b>Quality ID 345:</b> Rate of Asymptomatic Patients Undergoing Carotid Artery Stenting (CAS) Who Are Stroke Free or Discharged Alive</li> <li>• <b>Quality ID 346:</b> Rate of Asymptomatic Patients Undergoing Carotid Endarterectomy (CEA) Who Are Stroke Free or Discharged Alive</li> <li>• <b>Quality ID 347:</b> Rate of Endovascular Aneurysm Repair (EVAR) of Small or</li> </ul>	<ul style="list-style-type: none"> <li>• <b>113:</b> Colorectal Cancer Screening</li> <li>• <b>117:</b> Diabetes: Eye Exam</li> <li>• <b>119:</b> Diabetes: Medical Attention for Nephropathy</li> <li>• <b>128:</b> Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up Plan</li> <li>• <b>134:</b> Preventive Care and Screening: Screening for Depression and Follow-Up Plan</li> <li>• <b>143:</b> Oncology: Medical and Radiation – Pain Intensity Quantified</li> <li>• <b>144:</b> Oncology: Medical and Radiation - Plan of Care for Pain</li> <li>• <b>176:</b> Rheumatoid Arthritis (RA): Tuberculosis Screening</li> <li>• <b>177:</b> Rheumatoid Arthritis (RA): Periodic Assessment of Disease Activity</li> <li>• <b>178:</b> Rheumatoid Arthritis (RA): Functional Status Assessment</li> <li>• <b>180:</b> Rheumatoid Arthritis (RA): Glucocorticoid Management</li> <li>• <b>181:</b> Elder Maltreatment Screen and Follow-Up Plan</li> <li>• <b>182:</b> Functional Outcome Assessment</li> <li>• <b>191:</b> Cataracts: 20/40 or Better Visual Acuity within 90 Days Following Cataract Surgery</li> <li>• <b>217:</b> Functional Status Change for Patients with Knee Impairments</li> <li>• <b>218:</b> Functional Status Change for Patients with Hip Impairments</li> <li>• <b>219:</b> Functional Status Change for Patients with Lower Leg, Foot or Ankle Impairments</li> <li>• <b>220:</b> Functional Status Change for Patients with Low Back Impairments</li> <li>• <b>221:</b> Functional Status Change for Patients with Shoulder Impairments</li> <li>• <b>222:</b> Functional Status Change for Patients with Elbow, Wrist or Hand Impairments</li> <li>• <b>226:</b> Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention</li> <li>• <b>236:</b> Controlling High Blood Pressure</li> <li>• <b>238:</b> Use of High-Risk Medications in the Elderly</li> <li>• <b>240:</b> Childhood Immunization Status</li> </ul>	
-----------------------	--	--	--

<p><b>Quality</b></p>	<p>Moderate NonRuptured Infrarenal Abdominal Aortic Aneurysms (AAA) Who Are Discharged Alive</p> <ul style="list-style-type: none"> <li>• <b>Quality ID 352:</b> Total Knee Replacement: Preoperative Antibiotic Infusion with Proximal Tourniquet</li> <li>• <b>Quality ID 353:</b> Total Knee Replacement: Identification of Implanted Prosthesis in Operative Report</li> <li>• <b>Quality ID 361:</b> Optimizing Patient Exposure to Ionizing Radiation: Reporting to a Radiation Dose Index Registry</li> <li>• <b>Quality ID 362:</b> Optimizing Patient Exposure to Ionizing Radiation: Computed Tomography (CT) Images Available for Patient Follow-up and Comparison Purposes</li> <li>• <b>Quality ID 371:</b> Depression Utilization of the PHQ-9 Tool</li> <li>• <b>Quality ID 372:</b> Maternal Depression Screening</li> <li>• <b>Quality ID 388:</b> Cataract Surgery with Intra-Operative Complications (Unplanned Rupture of Posterior Capsule Requiring Unplanned Vitrectomy)</li> <li>• <b>Quality ID 403:</b> Adult Kidney Disease: Referral to Hospice</li> <li>• <b>Quality ID 407:</b> Appropriate Treatment of Methicillin-Susceptible Staphylococcus Aureus (MSSA) Bacteremia</li> <li>• <b>Quality ID 411:</b> Depression Remission at Six Months</li> <li>• <b>Quality ID 417:</b> Rate of Open Repair of Small or Moderate NonRuptured Infrarenal Abdominal Aortic Aneurysms (AAA) Where Patients Are Discharged Alive</li> <li>• <b>Quality ID 428:</b> Pelvic Organ Prolapse: Preoperative</li> </ul>	<ul style="list-style-type: none"> <li>• <b>243:</b> Cardiac Rehabilitation Patient Referral from an Outpatient Setting</li> <li>• <b>268:</b> Epilepsy: Counseling for Women of Childbearing Potential with Epilepsy</li> <li>• <b>282:</b> Dementia: Functional Status Assessment</li> <li>• <b>283:</b> Dementia Associated Behavioral and Psychiatric Symptoms Screening and Management</li> <li>• <b>286:</b> Dementia: Safety Concern Screening and Follow-Up for Patients with Dementia</li> <li>• <b>288:</b> Dementia: Education and Support of Caregivers for Patients with Dementia</li> <li>• <b>290:</b> Parkinson’s Disease: Psychiatric Symptoms Assessment for Patients with Parkinson’s Disease</li> <li>• <b>305:</b> Initiation and Engagement of Alcohol and Other Drug Dependence Treatment</li> <li>• <b>317:</b> Preventive Care and Screening: Screening for High Blood Pressure and Follow-Up Documented</li> <li>• <b>326:</b> Atrial Fibrillation and Atrial Flutter: Chronic Anticoagulation Therapy</li> <li>• <b>332:</b> Adult Sinusitis: Appropriate Choice of Antibiotic: Amoxicillin With or Without Clavulanate Prescribed for Patients with Acute Bacterial Sinusitis (Appropriate Use)</li> <li>• <b>335:</b> Maternity Care: Elective Delivery or Early Induction Without Medical Indication at &lt; 39 Weeks (Overuse)</li> <li>• <b>336:</b> Maternity Care: Postpartum Follow-up and Care Coordination</li> <li>• <b>337:</b> Psoriasis: Tuberculosis (TB) Prevention for Patients with Psoriasis, Psoriatic Arthritis and Rheumatoid Arthritis on a Biological Immune Response Modifier</li> <li>• <b>342:</b> Pain Brought Under Control Within 48 Hours</li> <li>• <b>348:</b> Implantable Cardioverter-Defibrillator (ICD) Complications Rate</li> <li>• <b>370:</b> Depression Remission at Twelve Months</li> </ul>	
-----------------------	---	--	--

<p><b>Quality</b></p>	<p>Assessment of Occult Stress Urinary Incontinence</p> <ul style="list-style-type: none"> <li>● <b>Quality ID 442:</b> Persistence of Beta-Blocker Treatment After a Heart Attack</li> <li>● <b>Quality ID 446:</b> Operative Mortality Stratified by the Five STSEACTS Mortality Categories</li> <li>● <b>Quality ID 449:</b> HER2 Negative or Undocumented Breast Cancer Patients Spared Treatment with HER2- Targeted Therapies</li> <li>● <b>Quality ID 454:</b> Percentage of Patients who Died from Cancer with More than One Emergency Department Visit in the Last 30 Days of Life (lower score – better)</li> <li>● <b>Quality ID 456:</b> Percentage of Patients who Died From Cancer Not Admitted to Hospice (lower score – better)</li> <li>● <b>Quality ID 467:</b> Developmental Screening in the First Three Years of Life</li> <li>● <b>Quality ID 474:</b> Zoster (Shingles) Vaccination</li> </ul>	<ul style="list-style-type: none"> <li>● <b>377:</b> Functional Status Assessments for Congestive Heart Failure</li> <li>● <b>378:</b> Children Who Have Dental Decay or Cavities</li> <li>● <b>379:</b> Primary Caries Prevention Intervention as Offered by Primary Care Providers, including Dentists</li> <li>● <b>382:</b> Child and Adolescent Major Depressive Disorder (MDD): Suicide Risk Assessment</li> <li>● <b>385:</b> Adult Primary Rhegmatogenous Retinal Detachment Surgery: Visual Acuity Improvement Within 90 Days of Surgery</li> <li>● <b>391:</b> Follow-up After Hospitalization for Mental Illness (FUH)</li> <li>● <b>392:</b> Cardiac Tamponade and/or Pericardiocentesis Following Atrial Fibrillation Ablation</li> <li>● <b>393:</b> Infection within 180 Days of Cardiac Implantable Electronic Device (CIED) Implantation, Replacement, or Revision</li> <li>● <b>394:</b> Immunizations for Adolescents</li> <li>● <b>405:</b> Appropriate Follow-up Imaging for Incidental Abdominal Lesions</li> <li>● <b>415:</b> Emergency Medicine: Emergency Department Utilization of CT for Minor Blunt Head Trauma for Patients Aged 18 Years and Older</li> <li>● <b>416:</b> Emergency Medicine: Emergency Department Utilization of CT for Minor Blunt Head Trauma for Patients Aged 2 through 17 Years</li> <li>● <b>418:</b> Osteoporosis Management in Women Who Had a Fracture</li> <li>● <b>438:</b> Statin Therapy for the Prevention and Treatment of Cardiovascular Disease</li> <li>● <b>439:</b> Age Appropriate Screening Colonoscopy</li> <li>● <b>440:</b> Skin Cancer: Biopsy Reporting Time – Pathologist to Clinician</li> <li>● <b>448:</b> Appropriate Workup Prior to Endometrial Ablation</li> <li>● <b>450:</b> Trastuzumab Received By Patients With AJCC Stage I (T1c) – III And HER2 Positive Breast Cancer Receiving Adjuvant Chemotherapy</li> <li>● <b>459:</b> Back Pain After Lumbar Discectomy/Laminectomy</li> </ul>	
-----------------------	---	--	--

<p><b>Quality</b></p>		<ul style="list-style-type: none"> <li>• <b>460:</b> Back Pain After Lumbar Fusion</li> <li>• <b>461:</b> Leg Pain After Lumbar Discectomy/Laminectomy</li> <li>• <b>462:</b> Bone Density Evaluation for Patients with Prostate Cancer and Receiving Androgen Deprivation Therapy</li> <li>• <b>469:</b> Functional Status After Lumbar Fusion</li> <li>• <b>470:</b> Functional Status After Primary Total Knee Replacement</li> <li>• <b>471:</b> Functional Status After Lumbar Discectomy/Laminectomy</li> <li>• <b>472:</b> Appropriate Use of DXA Scans in Women Under 65 Years Who Do Not Meet the Risk Factor Profile for Osteoporotic Fracture</li> <li>• <b>473:</b> Leg Pain After Lumbar Fusion</li> <li>• <b>475:</b> HIV Screening</li> </ul>	
<p><b>Improvement Activities</b></p>	<ul style="list-style-type: none"> <li>• <b>Activity ID IA_PM_1:</b> Participation in Systematic Anticoagulation Program</li> <li>• <b>IA_CC_3:</b> Implementation of additional activity as a result of TA for improving care coordination</li> <li>• <b>IA_PSPA_14:</b> Participation in Quality Improvement Initiatives</li> <li>• <b>IA_PSPA_5:</b> Annual Registration in the Prescription Drug Monitoring Program</li> <li>• <b>IA_PSPA_24:</b> Initiate CDC Training on Antibiotic Stewardship</li> <li>• <b>IA_BMH_3:</b> Unhealthy alcohol use</li> <li>• <b>IA_BE_11:</b> Participation in a QCDR, that promotes use of processes and tools that engage patients for adherence to treatment plan</li> <li>• <b>IA_BE_2:</b> Use of QCDR to support clinical decision making</li> <li>• <b>IA_BE_9:</b> Use of QCDR patient experience data to inform and advance improvements in beneficiary</li> </ul>	<ul style="list-style-type: none"> <li>• <b>Activity ID IA_PSPA_28:</b> Completion of an Accredited Safety or Quality Improvement Program</li> <li>• <b>IA_PM_2:</b> Anticoagulant Management Improvements</li> <li>• <b>IA_EPA_4:</b> Additional improvements in access as a result of QIN/QIO TA</li> <li>• <b>IA_PSPA_19:</b> Implementation of formal quality improvement methods, practice changes, or other practice improvement processes</li> <li>• <b>IA_BE_7:</b> Participation in a QCDR, that promotes use of patient engagement tools</li> <li>• <b>IA_PSPA_7:</b> Use of QCDR data for ongoing practice assessment and improvements</li> <li>• <b>IA_BMH_10:</b> Completion of Collaborative Care Management Training Program</li> </ul>	<ul style="list-style-type: none"> <li>• <b>Activity ID IA_BE_25:</b> Drug Cost Transparency</li> <li>• <b>IA_CC_18:</b> Tracking of clinician's relationship to and responsibility for a patient by reporting MACRA patient relationship codes</li> </ul>

<b>Improvement Activities</b>	<ul style="list-style-type: none"> <li>• <b>IA_BE_10:</b> Participation in a QCDR, that promotes implementation of patient self-action plans.</li> <li>• <b>IA_CC_6:</b> Use of QCDR to promote standard practices, tools and processes in practice for improvement in care coordination</li> <li>• <b>IA_AHE_4:</b> Leveraging a QCDR for use of standard questionnaires</li> <li>• <b>IA_AHE_2:</b> Leveraging a QCDR to standardize processes for screening</li> <li>• <b>IA_PM_10:</b> Use of QCDR data for quality improvement such as comparative analysis reports across patient populations</li> <li>• <b>IA_CC_4:</b> TCPI Participation</li> </ul>		
<b>Promoting Interoperability</b>	<ul style="list-style-type: none"> <li>• Verify Opioid Treatment Agreement</li> </ul>	<ul style="list-style-type: none"> <li>• Query of Prescription Drug Monitoring Program (PDMP) – <i>changed to YES/NO attestation statement and remains an optional measure for 5 bonus points</i></li> </ul>	<ul style="list-style-type: none"> <li>• N/A</li> </ul>

**NOTE:** All measures not listed on this document are unchanged and still active for the 2020 reporting year.

**NOTE:** The Promoting Interoperability measures are not “selection” based like the Quality and Improvement Activities categories. All measures are required (in addition to the measures not listed here) except for the PDMP measure which is optional (with bonus points) for 2020.

1. Be aware of the measures/activities you are currently reporting.
2. Review the “Deleted” column.
  - a. If any of your current Quality measures are found in this column, it is imperative you replace the measure to begin collecting data on Jan. 1, 2020.
  - b. If any of your current Improvement Activities are found in this column find a new Improvement Activity to report on for a continuous 90-day period in 2020.
  - c. If none of your current measures or activities are found in the “Deleted” column then all your measures/activities are still active and can be reported for 2020, continue to the “Modified” column to check if your measures have changed or remained the same.
3. Review the “Modified” column.
  - a. If any of your current Quality measures are found in this column, review measures specifications found above in 2a. and make any necessary adjustments to continue reporting this measure appropriately for the 2020 performance year.
  - b. If any of your current Improvement activities are found in this column, the changes made can be found in Appendix 2 of the final rule.



4. If none of your current measures or activities are found in the “Modified” or “Deleted” column then all your measures/activities are still active for 2020 and you can continue reporting on them as you did in 2019.
5. Review the “Added” column if needed to find new measures/activities that may be well suited for your practice or specialty to report for the 2020 MIPS performance year.

**Call or email the HIT/Quality Coordinator for additional MIPS assistance at (713) 524-4267 or [quality@hcms.org](mailto:quality@hcms.org).**